Difference between revisions 607282201 and 607282626 on enwiki

'''Zerona''' is a low-level laser device developed by Erchonia Corp. for non-invasive body slimming of the waist, hips, and thighs. It has been shown to disrupt [[adipocyte]], or fat cell, membranes causing the release of stored [[lipids]] and fatty material, in turn, promoting adipocyte collapse. The device was first introduced to the market in 2008 as an [[off-label use]] device for slimming, but later was granted 510k market clearance{{jargon-inline|date=May2014}} by the [[F(contracted; show full)s pathways within a cell. However, as the concentration of ROS elevates a process known as [[lipid peroxidation]] can occur where ROS reacts with lipids found within cell membranes temporarily damaging them.<ref name=pmid16248161/><ref name=pmid8570716/> It has been hypothesized that the Zerona, as a low-level laser device, modulates cell metabolism resulting in a transient rise of ROS which temporarily degrades the membrane creating transitory pores or openings.

== Clinical trial ==
In 2008, 
the a [[clinical trial]] to investigate the efficacy of Zerona commencwas conducted. The trial enrolled 67 subjects, 35 of which were randomly assigned to receive active treatment with 32 randomly assigned to the control group. Both groups were asked to sign an affidavit stating that during the clinical trial they would make no changes to their lifestyle and would not participate in any other program or consume any supplements that would promote slimming. Furthermore, patients were asked to track their daily activities and caloric intake through the entire duration of the trial. This daily journal ensured that patients were not making any changes that could impact the outcome.⏎
Patients received treatment every-other day for two weeks receiving a total of 6 treatments. Patients' waist, hips, and thighs were treated concurrently for 40 total minutes each treatment, including 20 minutes of anterior or front treatment and 20 minutes of posterior or back treatment. Measurements were taken at baseline, weeks one and two, and a two-week post-procedure follow-up measurement. After two weeks the active treatment group averaged a cumulative reduction of 3.54&nbsp;inches compared t(contracted; show full)== References ==
{{reflist|2}}

==External links==
* [http://www.erchonia.com/ Erchonia Corp., Official Website]

[[Category:Laser medicine]]
[[Category:Management of obesity]]